サンプル依頼リスト カート
  • English
  • Korean
表紙：腸チフスの世界市場-2023年～2030年
市場調査レポート
商品コード
1352186

腸チフスの世界市場-2023年～2030年

Global Typhoid Fever Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 200 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
腸チフスの世界市場-2023年～2030年
出版日: 2023年09月27日
発行: DataM Intelligence
ページ情報: 英文 200 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

チフス菌は腸チフスの原因菌です。腸チフスは汚染された食物や水によって感染し、世界の多くの地域、特に衛生設備や清潔な水へのアクセスが不十分な地域において、公衆衛生の大きなリスクとなっています。市場の大部分を占めるのは腸チフス治療薬、予防接種、診断薬です。

腸チフスをはじめとする感染症は、国際機関や各国政府からの注目度が高まっています。関連製品の市場を牽引しているのは、衛生環境、衛生、予防接種の普及率を高める取り組みです。

予防措置に対する需要の増加は、腸チフスのリスクに関する一般市民の意識向上努力の結果であり、予防接種や治療薬の入手も可能です。腸チフス予防接種市場は、更新された新しい予防接種のリリースから恩恵を受けています。予防接種の需要は、より多くの国が予防接種プログラムを実施するにつれて高まっています。

ダイナミクス

ワクチン接種プログラムの増加

2023年7月、生後9ヵ月から65歳までのすべての人に予防接種を行うため、フィジー保健医療サービス省（MHMS）は北部地域で腸チフスに対する集団予防接種プログラムを開始しました。国際ワクチン研究所（IVI）が、フィジー保健医療省、ピーター・ドハティ研究所およびマードック小児研究所の科学者と協力して指揮している「フィジーにおける腸チフス-撲滅に向けたワクチン接種（Ty-FIVE）」プロジェクトは、公衆衛生キャンペーンをその構成要素のひとつに含んでいます。

今後8週間にわたり、北部支部の医療関係者は、Typbar腸チフス結合型ワクチンを約13万2000人に1回接種します。Ty-FIVEは、キャンペーン終了後、収集したデータを用いて、流行状況における予防接種の有効性を評価します。

腸チフスの有病率の上昇

チフス菌は、致死的な病気である腸チフスの原因菌です。米国では年間5,700人が発症していると考えられています。症例の最大75％は海外旅行中に感染します。未開発の世界では、年間約2,150万人が腸チフスに感染しています。腸チフス患者は通常、華氏103度から104度（摂氏39度から40度）の熱が続きます。

さらに、脱力感や頭痛、吐き気、腹痛を感じることもあります。状況によっては、平らなバラ色の発疹が出ることもあります。腸チフスと確実に診断できるのは、便または血液からチフス菌を検出する検査のみです。どちらの腸チフスワクチンも50％～80％の予防効果がありますが、腸チフスの可能性もあることを旅行者は知っておく必要があります。

政府の取り組み

2022年9月現在、クエッタの39の都市連合評議会では、9歳から15歳までの856,000人の子どもたちが、第一段階で腸チフスワクチンの接種を受けることになっています。相談会の参加者は、パキスタンには医学的な治療はできませんが、ワクチン接種によって予防できる腸チフスの株があることを知らされました。バロチスタン州は腸チフス撲滅キャンペーンを開始しました。

PHC Globalは州政府と協力して、ラスベラ、ケチ、ジャファラバード、クエッタを含むバロチスタン4地区でこのワクチン接種に取り組んでいます。ワクチン接種による悪影響はありません。クエッタ保健省は、意識向上の必要性を強調し、腸チフスワクチン・プログラムは新しいものであるため、一般市民への啓発キャンペーンを推進する必要があり、そのためには市民社会やメディアを含むすべての利害関係者がそれぞれの役割を果たす必要があると付け加えました。

研究活動の拡大

パキスタンにおける薬剤耐性腸チフスの予防と対応活動を改善するため、専門家は腸チフス結合型ワクチン（TCV）接種のためらいや接種機会、水・衛生・清潔に関する習慣を危険因子として評価しています。パキスタン疫学研修プログラムでは、この分野で必要なスキルを身につけるため、腸チフスのモニタリングとアウトブレイク対応に関する研修資料を作成し、実施する予定です。

TCVワクチン接種戦略は、抗菌薬耐性株のさらなる蔓延を防ぎ、現在利用可能な経口抗生物質すべてに耐性を持つ株の発生リスクを低減するのに役立ちます。これは特に、腸チフスの死亡率が高い低・中所得国で大きな効果が期待されます。パキスタンで発生した薬剤耐性腸チフス（XDR）には、治療の選択肢がほとんどありません。

ワクチン接種への抵抗感

ワクチン接種施設があるにもかかわらず、ワクチン接種をためらったり、拒否したりすること。ワクチン接種のためらいは、誤った情報、医療システムに対する信頼の欠如、文化的規範、ワクチンの安全性に対する不安など、さまざまな要因によって引き起こされます。ワクチンに関する誤った情報は、副作用や陰謀論に関する誤った主張など、ワクチン接種への消極的な姿勢や不本意さを引き起こす可能性があります。

ワクチン接種へのためらいは、医療従事者、医療施設、ワクチン製造者に対する信頼の欠如によって悪化することもあります。腸チフスのリスクが低い地域や重症化しないと思われる地域では、人々はワクチン接種を優先しません。文化によっては、文化的または宗教的信念が予防接種の見方に影響を与え、予防接種を嫌がる原因となっている場合もあります。

腸チフスワクチンの副作用

経口のTy21aワクチンと注射のVi多糖体ワクチンは、最も広く使用されている2つの腸チフスワクチンです。どちらのワクチンも一般的に安全ですが、他の医療行為と同様に副作用が出ることがあります。副作用は人によって異なり、その大部分は軽微で一過性のものです。Vi多糖体ワクチンの注射を受けた際に、注射部位に軽度の不快感、発赤、腫れが生じる患者もいます。

吐き気、下痢、腹痛のような軽度の胃腸症状が起こる人もいます。まれに、予防接種後に副反応が起こることがあります。じんましん、呼吸困難、首の腫れ、呼吸困難はすべてアレルギー反応の兆候です。このような症状が現れた場合は、救急医療機関を受診するべきでる。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • ワクチン接種プログラムの増加
      • 腸チフスの有病率の上昇
      • 政府の取り組み
      • 研究活動の拡大
    • 抑制要因
      • ワクチン接種への抵抗感
      • 腸チフスワクチンに関連する副作用
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • ロシア・ウクライナ戦争の影響分析
  • DMIの見解

第6章 COVID-19分析

第7章 タイプ別

  • 生ワクチン
  • 一価腸チフスワクチン
  • 莢膜多糖体ワクチン
  • 結合型ワクチン
  • その他

第8章 投与経路別

  • 経口
  • 非経口

第9章 エンドユーザー別

  • 病院
  • 専門クリニック
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • Emergent
    • 企業概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な動向
  • Bharat Biotech
  • Bio Med
  • GlaxoSmithKline plc
  • Sanofi
  • Merck & Co., Inc.
  • Others

第13章 付録

目次
Product Code: PH6956

Overview

Salmonella Typhi is the bacterium that causes typhoid fever. It is spread by tainted food and water and is a major public health risk in many parts of the world, especially in those with poor access to sanitary facilities and clean water. Typhoid fever treatments, vaccinations, and diagnostics make up the majority of the market.

Typhoid fever and other infectious diseases are receiving more attention from international organizations and governments. The market for related products is driven by initiatives to enhance sanitation, hygiene, and immunization coverage.

Increased demand for preventive measures is a result of public awareness efforts about the risks of typhoid fever as well as the availability of vaccinations and therapies. The market has benefited from the release of updated and new typhoid vaccinations. The demand for vaccinations rises as more nations implement vaccination programs.

Dynamics

Increasing Vaccination Program

In July 2023, in order to immunize every person between the ages of 9 months and 65, the Ministry of Health and Medical Services (MHMS) of Fiji initiated a mass vaccination program against typhoid in the Northern Division. The Typhoid in Fiji - Vaccination Toward Elimination (Ty-FIVE) project, which is being directed by the International Vaccine Institute (IVI) in collaboration with the Fijian MHMS and scientists from the Peter Doherty Institute and Murdoch Children's Research Institute, includes the public health campaign as one of its components.

Over the next 8 weeks, medical professionals in the Northern Division will give the Typbar typhoid conjugate vaccine to almost 132,000 individuals in a single dosage. Ty-FIVE will use the data gathered to evaluate the effectiveness of prophylactic immunization in an endemic context after the campaign.

The Increasing Prevalence of Typhoid Fever

The bacteria Salmonella Typhi is the source of the potentially fatal disease typhoid fever. In the US, there are thought to be 5,700 instances yearly. Up to 75% of cases are contracted when traveling abroad. In the underdeveloped world, where it affects roughly 21.5 million people yearly, typhoid fever is still widespread. Typhoid fever patients typically have a persistent temperature of 103° to 104° F (39° to 40° C).

Additionally, they can feel weak or experience headaches, nausea, or stomachaches. Patients may get a rash of flat, rose-colored patches in some circumstances. Typhoid fever can only be diagnosed with certainty through testing of stool or blood samples for Salmonella Typhi. Travelers should be advised that while both typhoid vaccines offer 50%-80% protection to recipients, typhoid illness is still a possibility.

Government Initiatives

As of September 2022, in Quetta's 39 urban union councils, 856,000 children between the ages of nine and fifteen would receive the typhoid vaccine during the first phase. Participants in the consultation session were informed that there is a strain of typhoid in Pakistan that cannot be treated medically but can be prevented by vaccination. Balochistan has begun an anti-typhoid campaign.

PHC Global is collaborating with the province government on this vaccination effort in four Balochistan districts, including Lasbela, Kech, Jafarabad, and Quetta. The vaccination had no negative side effects. DHO Quetta emphasized the necessity for raising awareness and added that as the typhoid vaccine program is new, it is necessary to promote awareness campaigns for the general public, for which all stakeholders, including civil society and the media, must play their respective roles.

The Increasing Research Activities

Typhoid conjugate vaccine (TCV) hesitancy and access, as well as practices related to water, sanitation, and hygiene, are among the risk factors that experts are evaluating in order to improve ongoing prevention and response efforts for drug-resistant typhoid in Pakistan. To equip the Pakistan Field Epidemiology Training Program with the necessary skills in this subject area, work will entail creating and implementing training materials for typhoid monitoring and outbreak response.

TCV vaccination strategies can help prevent the further spread of antimicrobial-resistant strains and reduce the risk of the development of a strain resistant to all currently available oral antibiotics, which could result in high typhoid-associated mortality in low- and middle-income countries. Extensively drug-resistant (XDR) typhoid outbreaks in Pakistan have few treatment options.

Vaccine Hesitancy

Despite the availability of vaccination facilities, vaccine hesitancy refers to the hesitation or refusal to obtain vaccinations. It can be influenced by a number of things, such as false information, a lack of faith in healthcare systems, cultural norms, and worries about the safety of vaccines. Misinformation about vaccines can cause reluctance and unwillingness to vaccinate, such as erroneous claims about side effects or conspiracy theories.

Vaccine hesitation may be exacerbated by a lack of faith in medical professionals, healthcare facilities, or vaccine producers. People do not prioritize vaccination in areas where the risk of typhoid fever is low or the illness is not thought to be severe, which results in delayed or skipped immunization. Some cultures may have cultural or religious beliefs that affect how they view vaccinations and cause reluctance.

Side Effects of Typhoid Vaccine

The oral Ty21a vaccine and the injectable Vi polysaccharide vaccine are the two most widely used typhoid vaccines. Although both vaccines are typically safe, they can have negative effects like any other medical procedure. The side effects can differ from person to person and the majority are minor and transient. Some patients encounter minor discomfort, redness, or swelling at the injection site upon receiving the injectable Vi polysaccharide vaccination.

Mild gastrointestinal symptoms like nausea, diarrhea, or stomach aches can occur in some persons. Although uncommon, adverse reactions can happen following immunization. Hives, breathing problems, neck swelling, or trouble breathing are all indications of an allergic reaction. Seek emergency medical treatment if you encounter any of these symptoms.

Segment Analysis

The global typhoid fever market is segmented based on type, route of administration, end-users and region.

Live Attenuated Vaccine

A live attenuated vaccination for oral administration exclusively, Vivotif (Typhoid vaccination Live Oral Ty21a). Salmonella typhi Ty21a, an attenuated strain, is present in the vaccine. Crucell Switzerland LTD is the company that makes Vivotif. The vaccine strain is cultivated in fermentors under carefully regulated circumstances using a medium that includes an acid digest of casein, dextrose, and galactose, as well as a digest of yeast extract. By centrifuging, the bacteria are separated, combined with a stabilizer made of sucrose, ascorbic acid, and amino acids, and then lyophilized.

In order to make the lyophilized bacteria resistant to stomach acid disintegration, they are combined with lactose and magnesium stearate and put inside gelatin capsules. The capsules are then coated with an organic solution. Vivotif (Typhoid Vaccine Live Oral Ty21a) is recommended for use in immunizing adults and children older than 6 years old against Salmonella typhi-related illness.

Geographical Penetration

The Increasing Number of Patients with Typhoid Fever in Asian Countries

Asia Pacific has been a dominant force in the global typhoid fever market. India has a high incidence of typhoid cases and the disease is endemic there. Affected areas are those with insufficient sanitation and hygiene standards. Varying states and areas have varying incidence rates. In some parts of Vietnam, typhoid fever is common, particularly in rural areas with little access to sanitary services and clean water.

Enteric fever (EF), also known as typhoid and paratyphoid fever, typically manifests as febrile symptoms accompanied by chills. A few individuals also appear with rose spots, which are typically challenging to recognize from other acute febrile infections. The majority of patients also come with gastrointestinal symptoms like abdominal pain, constipation, and diarrhea.

As per the article published in BMC Public Health in 2023, typhoid and paratyphoid are common throughout Asia, which includes China. Typhoid and paratyphoid fever are widespread in Southeast Asia, with India bearing a disproportionately heavy burden and accounting for roughly half of all deaths worldwide. China, which is a part of Asia, should monitor the situation of the disease that is coming from Southeast Asia and implement entry-exit quarantine measures.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global typhoid fever market. The COVID-19 pandemic has made it clear how crucial it is to prevent and manage infectious diseases. More funding is given by governments and healthcare institutions to combat COVID-19 as well as other infectious diseases like typhoid fever.

Due to lockdowns and health system priorities, certain regular vaccination campaigns, such as those for typhoid fever interrupted during the pandemic. Typhoid outbreaks could possibly become more likely in some areas as a result of this disruption, which could result in decreased vaccination coverage rates.

Russia-Ukraine War Impact Analysis

Conflicts can disrupt healthcare systems, making it difficult to provide basic medical services including typhoid fever diagnosis, treatment, and prevention. People are frequently displaced during conflicts as they flee their homes in search of safety. Displacement can result in congested living quarters, restricted access to sanitary services and clean water, as well as a higher risk of infectious diseases like typhoid.

Conflict-related infrastructure damage can affect water and sanitation systems, which raises the risk of waterborne illnesses like typhoid fever. Conflicts can stop routine vaccination campaigns, which lowers vaccination coverage rates and raises susceptibility to diseases that can be prevented by vaccination.

By Type

  • Live Attenuated Vaccine
  • Monovalent Typhoid Vaccines
  • Capsular Polysaccharide Vaccines
  • Conjugate Vaccine
  • Others

By Route of Administration

  • Oral
  • Parenteral

By End-users

  • Hospitals
  • Specialty Clinics
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • In May 2023, the Government of Malawi launched a nationwide integrated vaccine campaign to distribute measles-rubella (MR) vaccines and typhoid conjugate vaccine (TCV), with assistance from Gavi, the Vaccine Alliance, WHO, UNICEF, TyVAC, and other partners. TCV will then be incorporated into the country's routine immunization program.

Competitive Landscape

The major global players in the market include Emergent, Bharat Biotech, Bio Med, GlaxoSmithKline plc., Sanofi, and Merck & Co., Inc. and others.

Why Purchase the Report?

  • To visualize the global typhoid fever market segmentation based on type, route of administration, end-users and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of typhoid fever market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global typhoid fever market report would provide approximately 57 tables, 64 figures and 200 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Route of Administration
  • 3.3. Snippet by End-users
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Vaccination Program
      • 4.1.1.2. The Increasing Prevalence of Typhoid Fever
      • 4.1.1.3. Government Initiatives
      • 4.1.1.4. The Increasing Research Activities
    • 4.1.2. Restraints
      • 4.1.2.1. Vaccine Hesitancy
      • 4.1.2.2. Side effects Associated with Typhoid Vaccine
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Russia-Ukraine War Impact Analysis
  • 5.6. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Live Attenuated Vaccine*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Monovalent Typhoid Vaccines
  • 7.4. Capsular Polysaccharide Vaccines
  • 7.5. Conjugate Vaccine
  • 7.6. Others

8. By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.1.2. Market Attractiveness Index, By Route of Administration
  • 8.2. Oral*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Parenteral

9. By End-users

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users
    • 9.1.2. Market Attractiveness Index, By End-users
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Specialty Clinics
  • 9.4. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Emergent*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Bharat Biotech
  • 12.3. Bio Med
  • 12.4. GlaxoSmithKline plc
  • 12.5. Sanofi
  • 12.6. Merck & Co., Inc.
  • 12.7. Others

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us